PCSK9 inhibitors: current status and emerging frontiers in lipid control
Related Experiment Video
Updated: Jul 10, 2025
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Federica Agnello1, Maria Sara Mauro1, Carla Rochira1
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.
Insights
Novel PCSK9 inhibitors effectively lower low-density lipoprotein cholesterol (LDL-C), reducing atherosclerotic cardiovascular disease (ASCVD) risk. Monoclonal antibodies show particular promise for high-risk patients, though cost and long-term effects require further study.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a major global health concern, with hypercholesterolemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), as a key modifiable risk factor.
- Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) plays a critical role in regulating LDL receptor levels, making it a target for novel lipid-lowering therapies.
Purpose of the Study:
- To review the structural and functional aspects of PCSK9 and its role in LDL receptor regulation.
- To explore various pharmacological strategies for PCSK9 inhibition.
- To evaluate the clinical evidence, safety, and efficacy of PCSK9 inhibitors in managing hypercholesterolemia and reducing cardiovascular risk.
Main Methods:
- Review of literature on PCSK9 structure, function, and regulation of LDL receptors.
- Exploration of diverse PCSK9 inhibition strategies: monoclonal antibodies, binding peptides, gene silencing, and active immunization.
- Analysis of clinical trial data assessing LDL-C reduction and cardiovascular outcomes associated with PCSK9 inhibitors.
Main Results:
- PCSK9 inhibitors, especially monoclonal antibodies, demonstrate significant efficacy in reducing LDL-C levels.
- Clinical trials confirm the safety and effectiveness of these inhibitors, with notable benefits for statin-intolerant and familial hypercholesterolemia patients.
- Long-lasting effects on LDL-C reduction and potential improvements in cardiovascular outcomes have been observed.
Conclusions:
- PCSK9 inhibition represents a significant advancement in managing hypercholesterolemia and reducing ASCVD risk.
- Monoclonal antibodies are a cornerstone therapy, offering substantial benefits for specific patient populations.
- Further research is needed to address cost-effectiveness and long-term safety considerations for widespread clinical application.
Introduction:
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global mortality, imposing substantial healthcare economic burdens. Among the modifiable risk factors, hypercholesterolemia, especially elevated low-density lipoprotein cholesterol (LDL-C), plays a pivotal role in ASCVD development. Novel therapies such as PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors are emerging to address this concern. These inhibitors offer the potential to reduce ASCVD risk by directly targeting LDL-C levels.
Areas Covered:
The article reviews the structural and functional aspects of PCSK9, highlighting its role in LDL receptor regulation. The pharmacological strategies for PCSK9 inhibition, including monoclonal antibodies, binding peptides, gene silencing, and active immunization, are explored. Clinical evidence from various trials underscores the safety and efficacy of PCSK9 inhibitors in reducing LDL-C levels and potentially improving cardiovascular outcomes. Despite these promising results, challenges such as cost-effectiveness and long-term safety considerations are addressed.
Expert Opinion:
Among PCSK9 inhibitors, monoclonal antibodies represent a cornerstone. Many trials have showed their efficacy in reducing LDL-C and the risk for major adverse clinical events, revealing long-lasting effects, with special benefits particularly for statin-intolerant and familial hypercholesterolemia patients. However, long-term impacts, high costs, and patient selection necessitate further research.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...